Overview: Cancer Antigen 72-4 (CA 72-4) TestIntroduction: The Cancer Antigen 72-4 Test measures CA 72-4, a cancer marker to monitor gastric cancer, causing stomach pain or weight loss. Aligned with 2023 NCCN guidelines, it uses an immunoassay for high sensitivity, aiding in cancer screening. This test is critical for guiding treatment monitoring, assessing disease progression, and improving outcomes in immunology for patients with suspected gastric cancer.
Other Names: CA 72-4 Assay, Gastric Cancer Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: CA 72-4 testing began in the 1990s with gastric cancer research. Immunoassays emerged in the 2000s, and by the 2010s, high-sensitivity assays improved monitoring accuracy.
Purpose: Monitors gastric cancer, guides treatment, and assesses disease progression in patients with stomach pain or weight loss.
Test Parameters: 1. CA 72.4
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like stomach pain or weight loss, and list medications like chemotherapy.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document stomach pain, weight loss, or family history of gastric cancer. Include current medications, especially chemotherapy or targeted therapies.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer treatment.
Procedural Considerations: Uses an immunoassay to measure CA 72-4 levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Benign gastrointestinal conditions may elevate CA 72-4 levels. Hemolysis or improper storage can degrade samples.
Clinical Significance: Elevated CA 72-4 levels indicate gastric cancer progression, prompting chemotherapy or surgery. Normal levels suggest stable disease or remission.
Specialist Consultation: Consult an oncologist for result interpretation. A gastroenterologist referral is advised for gastric cases.
Additional Supporting Tests: Endoscopy, abdominal CT, or CEA test to confirm gastric cancer or assess disease extent.
Test Limitations: False positives may occur with benign conditions like gastritis. Results require clinical correlation with imaging.
References: NCCN Gastric Cancer Guidelines, 2023; Journal of Clinical Oncology, Ajani JA, 2022.
